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Background
Intranasal/intratracheal (IN/IT) priming with replicating
adenovirus type 5 host range mutant (Ad5hr)-SIV recom-
binant vaccines plus envelope protein boosting elicits
potent, durable protection in rhesus macaques following
SIVmac251  challenge. The recent STEP trial outcome
prompted us to examine cell types infected, tissue distri-
bution and persistence of E3-deleted Ad5hr in vivo.
Methods
Ad5hr-SIVenv/rev, -SIVgag, and -GFP recombinants were
given to rhesus macaques by the IN/IT, sublingual, rectal
or vaginal routes at weeks 0 and 12. Controls received
Ad5hr-GFP only. Blood, bronchial alveolar lavage (BAL),
and rectal biopsies were collected one week after each Ad
immunization (weeks 1 and 13) and examined for GFP
expression among lymphocytes (CD3, CD4, CD8, B, NK),
macrophages, dendritic and epithelial cells by flow
cytometry. Two weeks post each Ad (weeks 2 and 14),
select macaques were sacrificed and multiple tissues fixed
for later histochemical staining. Flow analyses were also
expanded at necropsy to include jejunum, tonsils and
lymph nodes.
Results
At week 1, GFP was expressed in BAL and rectal macro-
phages and epithelial cells in all macaques, regardless of
immunization route, but was undetectable at week 2. In
contrast, more potent and sustained expression of GFP
was detected at both 13 and 14 weeks in high percentages
of macrophages, but not epithelial cells, in PBMCs, rec-
tum, jejunum and BAL, with expansion to BAL mDCs,
again irrespective of route.
Conclusion
Overall, the route of immunization did not impact the
level or location of Ad5hr replication in the macaque
model. Ad5hr serum neutralizing antibody was detected
after the first and boosted after the second Ad immuniza-
tion primarily in the IN/IT group, but did not affect GFP
expression or persistence within macrophages. It may
have played a role in loss of GFP expression in epithelial
cells after the second Ad. Measurement of SIV-specific
immunity and histochemical staining for Ad in tissues is
ongoing.
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